2009
Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy
Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy. Clinical Infectious Diseases 2009, 49: 1570-1578. PMID: 19845472, PMCID: PMC2783631, DOI: 10.1086/644772.Peer-Reviewed Original ResearchConceptsEarly discontinuationHIV infectionAntiretroviral therapyYears of lifeLate initiationRisk behaviorsLate presentationHuman immunodeficiency virus (HIV) infectionHIV Research NetworkLate treatment initiationCohort of HIVImmunodeficiency virus infectionLife expectancyStandardized mortality ratioGeneral US populationHigh-risk profileYears of ageHigh-risk behaviorsSimilar demographic characteristicsRace/ethnicityART discontinuationART initiationCare concordantHispanic HIVAdvanced disease
2006
Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients
Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s113-s118. PMID: 17133193, DOI: 10.1097/01.qai.0000248334.52072.25.Peer-Reviewed Original ResearchConceptsStandard careNursing interventionsClinical trialsLong-term survival benefitIncremental cost-effectiveness ratioCohort of HIVQuality-adjusted life yearsLifetime medical costsCost-effectiveness ratioVirologic suppressionAntiretroviral therapyViral suppressionAntiretroviral medicationsHIV diseaseSurvival benefitClinical outcomesAdherence interventionsAntiretroviral adherenceMedical costsLife yearsModest effectivenessPatientsInterventionAdherenceHIV
2003
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. The American Journal Of Medicine 2003, 115: 632-641. PMID: 14656616, DOI: 10.1016/j.amjmed.2003.07.007.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHuman immunodeficiency virus (HIV) infectionClinical trial cohortImmunodeficiency virus infectionAdvanced diseaseCost-effectiveness ratioAdherence interventionsAntiretroviral therapyTrial cohortEarly diseaseVirus infectionUrban cohortLife expectancyHIV ribonucleic acid levelsEffective adherence interventionsCD4 cell countCombination antiretroviral therapyVirologic failure ratesLow baseline levelsFailure rateRibonucleic acid levelsStandard careHIV infectionHealthy patientsClinical trials